Advertisement

Research Article Free access | 10.1172/JCI113594

Insulin-like growth factor-I can mediate autocrine proliferation of human small cell lung cancer cell lines in vitro.

Y Nakanishi, J L Mulshine, P G Kasprzyk, R B Natale, R Maneckjee, I Avis, A M Treston, A F Gazdar, J D Minna, and F Cuttitta

Navy Medical Oncology Branch, National Cancer Institute, Bethesda, Maryland 20814.

Find articles by Nakanishi, Y. in: PubMed | Google Scholar

Navy Medical Oncology Branch, National Cancer Institute, Bethesda, Maryland 20814.

Find articles by Mulshine, J. in: PubMed | Google Scholar

Navy Medical Oncology Branch, National Cancer Institute, Bethesda, Maryland 20814.

Find articles by Kasprzyk, P. in: PubMed | Google Scholar

Navy Medical Oncology Branch, National Cancer Institute, Bethesda, Maryland 20814.

Find articles by Natale, R. in: PubMed | Google Scholar

Navy Medical Oncology Branch, National Cancer Institute, Bethesda, Maryland 20814.

Find articles by Maneckjee, R. in: PubMed | Google Scholar

Navy Medical Oncology Branch, National Cancer Institute, Bethesda, Maryland 20814.

Find articles by Avis, I. in: PubMed | Google Scholar

Navy Medical Oncology Branch, National Cancer Institute, Bethesda, Maryland 20814.

Find articles by Treston, A. in: PubMed | Google Scholar

Navy Medical Oncology Branch, National Cancer Institute, Bethesda, Maryland 20814.

Find articles by Gazdar, A. in: PubMed | Google Scholar

Navy Medical Oncology Branch, National Cancer Institute, Bethesda, Maryland 20814.

Find articles by Minna, J. in: PubMed | Google Scholar

Navy Medical Oncology Branch, National Cancer Institute, Bethesda, Maryland 20814.

Find articles by Cuttitta, F. in: PubMed | Google Scholar

Published July 1, 1988 - More info

Published in Volume 82, Issue 1 on July 1, 1988
J Clin Invest. 1988;82(1):354–359. https://doi.org/10.1172/JCI113594.
© 1988 The American Society for Clinical Investigation
Published July 1, 1988 - Version history
View PDF
Abstract

The effect of insulin-like growth factor I (IGF-I) on growth of small cell lung cancer (SCLC) cell lines was studied. Western blot analysis of whole cell lysates of cell lines NCI-H345 and NCI-N417 demonstrated the presence of a 16-kD band consistent with an IGF-I precursor molecule. Scatchard plot analysis of cell line NCI-H345 using 125I-labeled IGF-I demonstrated two high affinity specific binding sites (Kd 1.3 and 4.0 nM with maximal rate (Bmax) 200 and 500 fmol/mg protein, respectively). The exogenous addition of IGF-I, IGF-II, or insulin resulted in marked proliferation of human SCLC cells as evaluated using an in vitro growth assay. These peptides stimulated the growth of SCLC cell lines NCI-H82, NCI-H209, NCI-H345, and NCI-N417. The concentration of IGF-I producing maximal SCLC cell growth was 10-100-fold less than that of insulin or IGF-II, whereas the maximal growth stimulated by the optimal concentration of these peptides were similar. An MAb that specifically binds to the IGF-I receptor (but not to the insulin receptor) mediates a dose-dependent inhibition of cell growth in basal media as well as IGF-I, IGF-II, or insulin-supplemented media. The IGF-I receptor thus appears to be the common pathway for the mitogenic activity by IGF-I, IGF-II, and insulin for human SCLC cell lines. The demonstration of an IGF-I precursor molecule, specific IGF-I receptor binding, IGF-I-mediated growth stimulation, and inhibition of basal cell growth by an MAb to the IGF-I receptor suggests that an IGF-I-like molecule can function in vitro as an autocrine growth factor for human SCLC cell lines.

Images.

Browse pages

Click on an image below to see the page. View PDF of the complete article

Version history
  • Version 1 (July 1, 1988): No description
Advertisement
Advertisement